CRChristophe Richez

Christophe Richez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christophe Richez has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Synthesis, Structural Analysis and Catalytic Activity of Stabilized Selenenyl Halides From the Reaction of 1,2‐Benzisoselenazoles With Carbon Electrophiles

    by Alexandre Karnat, Quentin Saros, Aline Lacoudre, Christophe Richez, Magali Szlosek, Eric Fouquet, Patrick Y. Toullec

    The synthesis of selenenyl halides stabilized by chalcogen bonding was accomplished by the reaction of benzisoselenazoles with a variety of carbon electrophiles under thermal activation. The X‐ray structures of five of these derivatives resulting from the oxidative addition of the carbon–halogen bond exhibited a stabilization by a Se–N interaction. These selenenyl halides react with organomagnesium reagents by substitution at the selenium center delivering a diarylselenide. The peroxidase and oxidase activities of the stabilized selenenyl halides were measured by UV–visible spectroscopy demonstrating the strong influence of the nitrogen substituent on the catalytic activities.

  • Open Access

    Metformin Added To First-Line Methotrexate In Methotrexate-Naïve Patients With Active Rheumatoid Arthritis (Metormet2): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial

    by Christophe Richez, Thomas Barnetche, Louis Bébéar, Carine Salliot, Emmanuelle Dernis, Amelie Denis, Alain Saraux, Jacques Morel, Adeline Ruyssen-Witrand, André Basch, et al.

    Background Methotrexate is the anchor first-line disease-modifying treatment for rheumatoid arthritis, yet many patients do not reach remission and strategies to potentiate the early treatment response are needed. Metformin has immunometabolic and anti-inflammatory properties, including attenuation of neutrophil extracellular trap formation and reactive oxygen species production, that could enhance the response to methotrexate. We aimed to determine whether adding metformin to methotrexate improves disease activity at 6 months in methotrexate-naïve patients with active rheumatoid arthritis.Methods METorMET2 was an investigator-initiated, multicentre, double-blind, placebo-controlled, parallel-group, phase 2 superiority trial done in 12 rheumatology centres in France. Eligible participants were adults (aged ≥18 years) with rheumatoid arthritis fulfilling the 2010 ACR/EULAR criteria, active disease (DAS28 >3·2), and no methotrexate or metformin in the previous 6 months; participants were not selected for body weight or metabolic status. Participants were randomly assigned (1:1, stratified by centre) to methotrexate plus metformin (titrated to a target of 1500 mg/day) or methotrexate plus matching placebo. Methotrexate was started at 10 mg/week and increased to 15 mg/week (up to 25 mg/week if needed). Participants, investigators, outcome assessors, and statisticians were masked to allocation. The primary outcome was DAS28-CRP at month 6, analysed as the adjusted between-group difference under a treatment-policy estimand with multiple imputation for missing data, in all randomly assigned eligible patients. The trial is registered with ClinicalTrials.gov (NCT04196868) and is complete.Findings Between December 2020, and June 2024, 128 patients were randomly assigned; 126 (65 metformin, 61 placebo) were eligible and analysed. Mean age was 57·9 years (SD 12·7), 89 (70·6%) of 126 participants were women, and median rheumatoid arthritis duration was 1 month (IQR 0·0–2·0). At month 6, mean DAS28-CRP was 2·8 (SD 1·1) with metformin and 2·9 (SD 1·3) with placebo; the adjusted between-group difference was −0·02 (95% CI −0·44 to 0·40; p=0·92). Results were consistent for the secondary estimand (−0·02, −0·46 to 0·41; p=0·92) and across all sensitivity analyses, all excluding the prespecified clinically relevant difference of 0·6 points. Remission was reached by 29 (48·3%) of 60 patients in the metformin group versus 30 (54·5%) of 55 in the placebo group. Serious adverse events occurred in 2 (3·1%) of 65 patients in the metformin group and 3 (4·9%) of 61 in the placebo group; gastrointestinal events were more frequent with metformin, and no deaths occurred.Interpretation Adding metformin 1500 mg/day to first-line methotrexate did not improve disease activity at 6 months in methotrexate-naïve patients with active rheumatoid arthritis and is not supported as an adjunct to methotrexate in this setting. Whether metabolism-targeting strategies benefit rheumatoid arthritis populations selected for metabolic dysfunction remains to be established.

  • Open Access

    Evaluation of pregnancy outcomes in patients with rheumatoid arthritis compared with the general population: results from a French national prospective and matched study.

    by Sabrina Hamroun, Grégoire Martin de Frémont, Nathalie Costedoat-Chalumeau, Marion Couderc, René-Marc Flipo, Laure Gossec, Christophe Richez, Rakiba Belkhir, Aline Frazier-Mironer, Valérie Devauchelle-Pensec, et al.

    The aim of the study was to assess the contemporary frequency of adverse pregnancy outcomes in women with rheumatoid arthritis (RA) and to identify associated factors. This French prospective multicentre cohort included pregnant women with RA between 2015 and 2021. Maternal characteristics, disease activity, treatments and pregnancy outcomes were analysed. Outcomes of pregnancies in women with RA were compared in univariable analysis with those of matched general population women from the 2016 and 2021 French perinatal surveys assessing maternal and neonatal health. Multivariable logistic regressions were performed to identify factors associated with adverse outcomes. A total of 100 pregnancies in 90 women with RA were analysed. Mean maternal age was 33.7±5.0 years and 57.6% were nulliparous. During pregnancy, 46% received glucocorticoids and 39% biologic disease-modifying antirheumatic drugs. Compared with the 359 controls from the general population, preterm birth (OR 2.08, 95% CI 1.04 to 4.09) and small for gestational age (SGA) (ORSGA 10th percentile 2.11, 95% CI 1.12 to 3.94; ORSGA 3rd percentile 3.21, 95% CI 1.13 to 9.44) rates were higher in RA pregnancies. SGA was associated with nulliparity (adjusted OR (aOR) 4.38, 95% CI 1.12 to 9.78), whereas preterm birth was associated with maternal age (aOR 1.14, 95% CI 1.01 to 1.30) and exposure to glucocorticoids at doses ≥10 mg/day during pregnancy (aOR 4.91, 95% CI 1.30 to 10.59). In this contemporary cohort mostly followed in tertiary care centres, pregnancies in women with RA remained at increased risk of preterm birth and SGA. Exposure to systemic glucocorticoids at doses ≥10 mg/day emerged as a risk factor for preterm birth, although a contribution of maternal disease activity cannot be entirely excluded.

  • Open Access

    Soluble CD95L triggers Caspase-10-driven reactive oxygen species production in neutrophils and aggravates anti-neutrophil cytoplasmic antibody-vasculitis

    by Andréa Boizard-Moracchini, Dhouha Msalbi, Sarah Huot-Marchand, Layla Haymour, Eden Lebrault, John Tchen, Titia Jekel, Gaël Galli, Benoît Brilland, Nathalie Mérillon, et al.

    Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a severe autoimmune disease that lacks effective targeted therapies. T cell and neutrophil activation are associated with tissue lesions in ANCA-associated vasculitis responsible for the necrotizing vasculitis of small blood vessels. Although the aberrant release of reactive oxygen species (ROS) by neutrophils contribute to the disruption of the endothelial barrier, the underlying molecular mechanisms of this oxidative burst remain unclear. Here, we observe that blood vessels in the inflamed organs of patients with AAV express CD95L, which is cleaved by metalloproteases to release soluble CD95L (sCD95L). sCD95L stimulates ROS production in AAV neutrophils via a caspase-driven mechanism. Proteomic analysis reveals that the deubiquitinase OTULIN is a caspase substrate in sCD95L-exposed neutrophils. Caspase-10 cleaves OTULIN after its aspartates at positions 31 and 54 to unleash the activity of E3 ligase complex LUBAC and trigger mitochondrion-dependent ROS production in AAV neutrophils. Inhibition of the CD95-mediated non-apoptotic signaling abrogates ROS production in AAV neutrophils and alleviates clinical symptoms in AAV and crescentic glomerulonephritis mouse models, indicating that CD95 and CD95L represent attractive molecular targets for patients with AAV.

  • Pharmacology considerations for managing pregnancy in women with systemic lupus erythematosus

    by Mayalen Uthurriague, Estibaliz Lazaro, Christophe Richez, Patrick Blanco, Noémie Gensous

    Pregnancy in women with systemic lupus erythematosus presents significant clinical challenges due to heightened risks of complications for both mother and fetus. Therapeutic management must be carefully tailored to safeguard maternal health while ensuring optimal fetal development. This review explores pharmacological treatments used during pregnancy in women with lupus, focusing on medication safety profiles, risk-benefit analyses of available therapeutic options, and specific challenges posed by comorbidities such as antiphospholipid syndrome and vaccination considerations. Although significant advances have been made in managing lupus during pregnancy, many treatments, particularly biologic therapies, still lack sufficient evidence for unrestricted use. This underscores the necessity for vigilant monitoring and individualized treatment protocols. Preconception consultation remains crucial for optimizing therapeutic strategies, ensuring appropriate medication adjustments prior to conception. A coordinated multidisciplinary approach is essential to navigate these complexities and achieve favorable outcomes for both mother and child.


  • Short telomere length is associated with accelerated lung disease progression in rheumatoid arthritis-associated interstitial lung disease

    by Kinan El Husseini, Joyce S. Lee, Pierre-Antoine Juge, Esther Ebstein, Sébastien Ottaviani, Raphaël Borie, Catherine Bancal, Marie-Pierre Debray, Caroline Kannengiesser, Ibrahima Ba, et al.

    Background: Shorter leukocyte telomere length (LTL) has been reported in patients with rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) and linked to increased disease severity and mortality in idiopathic pulmonary fibrosis, which shares similarities with RA-ILD. We aimed to evaluate the impact of short LTL on baseline respiratory disease severity, disease progression and survival in patients with RA-ILD. Methods: Patients diagnosed with RA-ILD following multidisciplinary assessment were enrolled in a prospective French observational study. LTL was measured at enrolment using qPCR. Short LTL was defined as age-adjusted LTL D LCO ) ≥10% predicted). Results: Among 101 patients with RA-ILD, 46% were male, mean± sd age at enrolment was 66±10 years and 43 (43%) had short LTL. Patients with short LTL had lower FVC % predicted (82% versus 93%) and D LCO % predicted (49% versus 63%) at enrolment, and greater 12-month decline in FVC % predicted and D LCO % predicted in mixed effects models (−7.7% (95% CI −11.6– −3.8%); pversus 22%; univariate p=0.011) and lower FVC at enrolment. Multivariate logistic regression identified lower FVC and short LTL as predictors of 12-month progression (OR 0.97 (95% CI 0.94–1.00); p=0.031 and OR 2.80 (95% CI 0.99–8.29); p=0.056, respectively). Conclusion: Short LTL is associated with baseline severity and 12-month progression in RA-ILD.


  • Open Access

    CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?

    by Maurine Jouret, Sebastien Viel, Benjamin Fournier, Sarah Benezech, Jérome Avouac, Marc Scherlinger, Alexandre Belot, Gaetane Nocturne, David Launay, Benjamin Terrier, et al.

    Chimeric antigen receptor (CAR) T-cell therapy targeting B cells has shown promising results, including drug-free remission, in adult-onset autoimmune diseases. Extending this therapeutic approach to the pediatric population, particularly for juvenile autoimmune diseases, presents an exciting opportunity. However, challenges specific to juvenile-onset autoimmune conditions, such as long-term adverse events, heightened disease activity, and the imperative to reduce steroid exposure, must be considered. While this strategy appears viable for these severe conditions, the limited data available for this population and the absence of evidence on cases with a high genetic component, such as monogenic lupus, represent significant challenges. Most monogenic lupus cases are associated with innate immune defects, and the involvement of B cells in these genetic anomalies remains poorly understood. In this review, we examine the potential indications, current knowledge, and limitations of CAR-T cell therapy in juvenile-onset autoimmune diseases, extending the discussion beyond early-onset lupus.


  • Open Access

    Analysis of the Impact of Tofacitinib Treatment on Weight and Body Mass Index in Patients With Rheumatoid Arthritis

    by Jürgen Wollenhaupt, Jacques Morel, Claire Daien, Adeline Ruyssen‐Witrand, Cédric Lukas, Christophe Richez, Andrea Shapiro, Douglass S. Chapman, Magali Cros, Jose L. Rivas, et al.

    Objectives: This post hoc analysis evaluated change from baseline (Δ) in weight/body mass index (BMI) and association with disease activity or lipid changes in tofacitinib‐treated patients with rheumatoid arthritis (RA).Methods: Data up to month 12 were pooled from eight phase 3 and 3b/4 studies of patients with RA receiving tofacitinib 5 or 10 mg twice daily or tofacitinib 11 mg modified‐release once daily (alone or combined with conventional synthetic disease‐modifying antirheumatic drugs), or placebo. Assessments included Δweight/BMI and the proportion of patients with weight gain ≥5%, at months 3, 6, and 12. Correlations between ∆weight/∆BMI and baseline/∆Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28‐4[ESR]), baseline C‐reactive protein (CRP), and ∆lipids were assessed. Statistical analysis included a longitudinal linear mixed model for repeated measures.Results: The analysis included 5,335 patients (tofacitinib 5 mg twice daily [n = 2,349], 10 mg twice daily [n = 1,611], 11 mg once daily [n = 694], and placebo [n = 681]). Increases in least squares mean Δweight and ΔBMI were significantly greater (P < 0.05) at months 3 and 6 with all tofacitinib doses versus placebo; increases continued to month 12. Significantly greater (at least P < 0.05) proportions of tofacitinib‐treated patients (all doses) had weight gain ≥5% at months 3 and 6 versus placebo. There were weak correlations between weight/BMI changes with tofacitinib and DAS28‐4(ESR), baseline CRP, or lipid changes.Conclusion: Patients receiving tofacitinib experienced weight and BMI changes (primarily increases) over time, with weak correlations with disease activity or lipids.


  • Open Access

    Efficacy of valaciclovir in preventing herpes zoster in patients receiving anifrolumab

    by Ludovic Trefond, Francois Chasset, Marie Jachiet, Cristina Livideanu, Thomas Barba, Stanislas Faguer, Julien Henry, Gaelle Richard-Colmant, Nicole Ferreira-Maldent, Sandrine Roque, et al.


  • Open Access

    Anti-CD20 alone as maintenance immunosuppressive therapy in severe lupus nephritis: a promising experience that needs to be evaluated

    by Sébastien Boutinet, Ludivine Lebourg, Stanislas Faguer, Christophe Richez, Noémie Jourde-Chiche, Eric Daugas

    Repeated flares of severe lupus nephritis (LN) (class III or IV LN in the ISN/RPS 2003 classification, with active lesions) are associated with a worse prognosis for kidney function and a higher risk of death. 1 Severe LN requires immunosuppressive therapy based on an initial therapy (formerly induction therapy) to achieve remission, followed by a maintenance or subsequent therapy to prevent flares. According to international recommendations, maintenance immunosuppressive therapy (MIST) consists of either mycophenolate or azathioprine, with mycophenolate being the most effective.2 3 However, there is no clear recommendation on how to manage the common situation of relapse of severe LN despite well-conducted MIST, or in cases of intolerance to standard MIST.